Innovative new technology has always been part of what makes ophthalmology an exciting specialty — and it has undeniably improved patient outcomes. But for surgeons who are early adopters, the flip side of being first is that one must also weather some financial uncertainties as new technologies, such as minimally invasive glaucoma surgery, corneal collagen cross-linking and sustained-release drugs, establish a solid reimbursement footing.
Products that are expected to be reimbursable, medically necessary services typically go through a three-step process: coding, coverage and payment.
1.
Uncategorized